ClinicalTrials.gg
RecruitingNCT07000409Updated Jun 5, 2025

The Effectiveness of Ultra-Sound Guided Erector Spinae Block With Betamethasone for Management of Truncal Chronic Post Herpetic Neuralgia.

An interventional study of Medical management regimen and Erector spinae plane (ESP) block in Postherpetic Neuralgia, Chronic Pain and Ultrasound Guidance, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-05.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Neuralgia, Postherpetic with a site in Egypt — 4 open to participants now, 4 under way, none of them phase 3. Neuralgia, Postherpetic · Egypt.

Planned enrollment
8th of 10
40 · median 56
Started
2025
with 4 others
No phase
9 of 10
4 open now
Registered
5th of 10
by date
Lead sponsor
2 of 10
Cairo University

Among the 10 studies in Neuralgia, Postherpetic with a site in Egypt, this one is the 8th largest by planned enrollment, is one of 5 that started in 2025, is one of 9 with no phase, and was the 5th registered.

Neuralgia, Postherpetic

197 studies on the registry are indexed under Neuralgia, Postherpetic; 29 are open to participants now.

Browse Neuralgia, Postherpetic studies →

Open to participants now

4 of the 10 studies in Neuralgia, Postherpetic with a site in Egypt are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 18 Neuralgia, Postherpetic studies recruiting now, 8 (44%) set no upper age limit and 5 (28%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Neuralgia, Postherpetic with a site in Egypt, or all of them as a file.
02

Study summary

To investigate the effectiveness of ultra-Sound guided Erector spinae block (ESB) with Betamethasone as an adjuvant to standard medical protocol in the management of truncal chronic post herpetic neuralgia.

Read the detailed description

Postherpetic neuralgia (PHN) is a syndrome described as zoster-associated pain persisting for more than 3 months after resolution of an initial herpes zoster (HZ) rash ("shingles").[This condition is considered to be the most prevalent and challenging complication associated with HZ infection. According to reports, around 75% of senior patients who contract HZ are likely to experience it. The incidence of it was observed to be 38.1%, 27.0%, and 19.0% at 1 month, 3 months, and 6 months, respectively, following the onset of zoster. Half of the patients who are more than 50 years have the risk of developing PHN. It is noteworthy that the incidence of PHN seems to be on the rise.

Erector spinae plane (ESP) block is one of the newer interfascial techniques where the drug is injected below the erector spinae muscle to spread towards the costotransverse foramina and origin of dorsal and ventral rami where it is supposed to work at the origin of spinal nerves, based on cadaveric and contrast studies. Cadaveric studies have also showed that a block at T5 level is sufficient to have unilateral multi-dermatomal sensory block ranging from T1 to L3. Thus, this block serves the purpose of a paravertebral block without the risk of pleural injury.

Betamethasone is a long-acting corticosteroid with immunosuppressive and anti-inflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity. The beneficial effects of injecting steroids could be because of sympathetic blockage, thereby inhibiting vasoconstriction and due to anaesthetization of the dorsal root ganglion and posterior spinal nerve.

03

Conditions studied

  • Postherpetic Neuralgia
  • Chronic Pain
  • Ultrasound Guidance
  • Erector Spinae Plane Block
  • Betamethasone
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients age between 18 and 75.
  • Patients with (ASA) II and III status.
  • Patients diagnosed with truncal chronic post herpetic neuralgia( neuropathic pain persistent for more than 3 months from the onset of rash appearance )

Exclusion criteria

Exclusion Criteria:

  • Patients unable to comprehend the .
  • Patients on long term opioid regimens.
  • Patients with impairment in hepatic ( (ALT) >50 U/L, and/or Aspartate aminotransferase (AST): >45 U/L) or renal functions( creatinine level ≥1.5 mg/dL)
  • Patients on anti-coagulation regimens.
  • Patients with coagulation abnormalities (i.e. (INR) ≥1.5 and/or ≤50000)
  • Local infection in the site of the block.
  • Patients with (BMI) > 35.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Med group

    Patients will receive the standard medical regimen alone.

    Other: Medical management regimen

  • Experimental
    Erector spinae plane block group

    Patients will receive erector spinae plane (ESP) block with betamethasone with standard medical regimen.

    Other: Erector spinae plane (ESP) block

Interventions

  • OtherMedical management regimen

    Patients will receive the standard medical regimen alone.

    Also known as: Paracetamol +-Gabapentin + Amitriptyline

  • OtherErector spinae plane (ESP) block

    Patients will receive erector spinae plane (ESP) block with betamethasone with standard medical regimen.

06

What researchers measure

Primary outcomes

  1. Pain degree

    The degree of pain will be obtained and recorded on a numeric rating scale (NRS) with 0=no pain, and 10=Maximum pain intensity. Pain NRS score will be assessed at 2,4,6,8 weeks after the first clinic visit.

    Time frame: 8 weeks after the first clinic visit.

Secondary outcomes

  1. Incidence of side effects

    Incidence of side effects for medications regimen (excessive sleepiness, nausea, vomiting allergic reaction, diarrhea, blurred vision, disorientation).

    Time frame: 8 weeks after the first clinic visit.

  2. Incidence of side effects

    Incidence of side effects for ESP block (local hematoma, limb numbness or weakness, dizziness, pneumothorax, hypotension, infection, allergic reaction).

    Time frame: 8 weeks after the first clinic visit.

  3. Tramadol consumption in both groups.

    Total consumption of tramadol in both groups will be recorded

    Time frame: 8 weeks after the first clinic visit.

07

Study locations

1 of 1 sites recruiting
  • Cairo University
    Cairo, 11651, Egypt
    Recruiting
    • Nada R Radwan, Master · Contactnadarefaat1994@gmail.com · 00201114595879
    • Amany E Ayad, MD · Sub investigator
    • Ahmed Z Mohamed, MD · Sub investigator
    • Marwa S Zayed, MD · Sub investigator
    • Ahmed M Mohamed, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

Time frame: After the end of study for one year.

Access criteria: The data will be available upon a reasonable request from the corresponding author.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2025, 7 months after the start.

Of 30 non-industry interventional studies with no phase under Neuralgia, Postherpetic, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's planned 7 months is below that.

Counting every sponsor, half of 32 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2025
First posted
Jun 2, 2025
StartActual
May 1, 2025
Primary completionEst.
Dec 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Jun 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07000409
Lead sponsor
Cairo University
Responsible party
Nada Refaat Eid (Assistant lecturer of Anesthesia, surgical ICU and pain management, Faculty of medicine, Cairo University, Cairo University) — Principal investigator
First posted
Jun 2, 2025
Start date
May 1, 2025
Primary completion
Dec 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Jun 5, 2025

Study contacts

Nada R Radwan, Master
Contact
nadarefaat1994@gmail.com
00201114595879

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion